13.20MMarket Cap-786P/E (TTM)
0.791High0.512Low1.12MVolume0.761Open0.760Pre Close716.85KTurnover8.57%Turnover RatioLossP/E (Static)18.04MShares2.33052wk High-1.89P/B9.57MFloat Cap0.40052wk Low--Dividend TTM13.09MShs Float8.180Historical High--Div YieldTTM36.72%Amplitude0.400Historical Low0.639Avg Price1Lot Size
NeuroSense Therapeutics Stock Forum
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
results from its 12-month PARADIGM Phase 2b study of PrimeC in ALS patients, showing a significant improvement in complication-free survival. Specifically, the study demonstrated a 57% difference in favor of PrimeC over placebo in the ITT population, and a 73% difference in the PP population. ...
Neurosense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living With ALS: The Promising Results From the 12-Month Paradigm Study Highlight Primec's Potential as a Disease Modifying Drug
No comment yet